Prostacyclin analogs and prostacyclin receptor agonists have effectively improved the quality of life of patients with PAH, although they have not been able to inhibit or reverse pulmonary vascular remodeling [232]. The gene discussed is PTGIR; the disease is pulmonary arterial hypertension.